Release Summary

Tenax Therapeutics, Inc. (NASDAQ: TENX), today provided update on pre-NDA meeting with FDA. LEVO-CTS shows 73% relative risk reduction in all-cause mortality at Day 90 for Isolated CABG patients.

Tenax Therapeutics, Inc.